Value of adiponectin as predictor of 5-year all-cause mortality in patients with symptomatic peripheral arterial disease: Results from the Linz Peripheral Arterial Disease (LIPAD) study

Clinica Chimica Acta

Volumn 408, Issue 1-2, 2009, Pages 87-91

  Dieplinger, Benjamin ^a   Haltmayer, Meinhard ^a   Poelz, Werner ^b   Mueller, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

Author keywords

Adipocytokines; Atherosclerosis; Mortality; Natriuretic peptides; Outcome; Prognosis

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADIPONECTIN; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 69849095642     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.07.014     Document Type: Article

References (24)

1. Weitz J.I., Byrne J., Clagett G.P., et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94 (1996) 3026-3049
2. Belch J.J., Topol E.J., Agnelli G., et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163 (2003) 884-892
3. Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 (1992) 381-386
4. Mueller T., Dieplinger B., Poelz W., Endler G., Wagner O.F., and Haltmayer M. Amino-terminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from the Linz Peripheral Arterial Disease Study. Clin Chem 55 (2009) 68-77
5. Haugen S., Casserly I.P., Regensteiner J.G., and Hiatt W.R. Risk assessment in the patient with established peripheral arterial disease. Vasc Med 12 (2007) 343-350
6. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 6 (2005) 7-14
7. Shimada K., Miyazaki T., and Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta 344 (2004) 1-12
8. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
9. Dieplinger B., Poelz W., Haltmayer M., and Mueller T. Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease. Clin Chem Lab Med 44 (2006) 830-833
10. Steffens S., and Mach F. Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. Circ Res 102 (2008) 218-225
11. Hajer G.R., van Haeften T.W., and Visseren F.L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 29 (2008) 2959-2971
12. Pilz S., Mangge H., Wellnitz B., et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 91 (2006) 4277-4286
13. Schnabel R., Messow C.M., Lubos E., et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J 29 (2008) 649-657
14. Dieplinger B., Poelz W., Haltmayer M., and Mueller T. Association of adiponectin and amino terminal proBNP in peripheral arterial disease. Clin Chim Acta 377 (2007) 192-197
15. Mueller T., Marschon R., Dieplinger B., et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study. J Vasc Surg 41 (2005) 808-815
16. Rutherford R.B., Baker J.D., Ernst C., et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26 (1997) 517-538
17. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index and mortality in patients with chronic heart failure. Circulation 112 (2005) 1756-1762
18. Dieplinger B., Gegenhuber A., Poelz W., Haltmayer M., and Mueller T. Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin Biochem 42 (2009) 1190-1193
19. Rathmann W., and Herder C. Adiponectin and cardiovascular mortality: evidence for "reverse epidemiology". Horm Metab Res 39 (2007) 1-2
20. Ang D.S., Welsh P., Watt P., Nelson S.M., Struthers A., and Sattar N. Serial changes in adiponectin and BNP in ACS patients: paradoxical associations with each other and with prognosis. Clin Sci (Lond) 117 (2009) 41-48
21. Sengenès C., Berlan M., De Glisezinski I., Lafontan M., and Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 14 (2000) 1345-1351
22. Tanaka T., Tsutamoto T., Sakai H., et al. Effect of atrial natriuretic peptide on adiponectin in patients with heart failure. Eur J Heart Fail 10 (2008) 360-366
23. Liu D., Schuster T., Baumann M., et al. Comparison of immunoassays for the selective measurement of human high-molecular weight adiponectin. Clin Chem 55 (2009) 568-572
24. Tsutamoto T., Tanaka T., Sakai H., et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 28 (2007) 1723-1730